Available to SourceHuman Prescription DrugOphthalmic & Otic

Retevmo (Selpercatinib)

80 mg/1 · Capsule

By Eli Lilly and Company

Selpercatinib · Capsule · 80 mg

NDC: 0002-2980
Route: Oral
Therapeutic class: Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor , Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]
Marketing category: NDA

Package sizes

60 CAPSULE in 1 BOTTLE (0002-2980-60)NDC 0002-2980-60Available to Order
120 CAPSULE in 1 BOTTLE (0002-2980-26)NDC 0002-2980-26Available to Order

Request This Medication

*Expect a reply within 2 business hours with availability and pricing.

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request a quote

Request this medication.

Pick the package size you need and we’ll respond with availability, lot details, dating, and pricing within 2 business hours. Mark it as Rush or Emergency if you need it faster.

DSCSA-compliant pedigree on every order
Cold-chain capable where applicable
Same-day fulfillment available for urgent needs

Related in Ophthalmic & Otic

See all →